Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/17/19
End: 06/30/23
Due: 06/30/24
Phase: N/A
Priority: Normal
Start: 02/12/22
End: 06/14/22
Due: 06/14/23
Phase: N/A
Priority: Normal
Start: 05/31/23
End: 09/30/28
Due: 09/30/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety Study of SLC-391 in Subjects With Solid Tumors | NCT03990454 | SignalChem Lifesciences Corporation | user2@example.com | None | 2019-09-17 | 2023-06-30 | 2024-06-30 | - | - | 2025-07-14 |
| Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects | NCT05278845 | SignalChem Lifesciences Corporation | user2@example.com | None | 2022-02-12 | 2022-06-14 | 2023-06-14 | - | - | 2025-07-14 |
| Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | NCT05860296 | SignalChem Lifesciences Corporation | user2@example.com | None | 2023-05-31 | 2028-09-30 | 2029-09-30 | - | - | 2025-07-14 |